Navigation Links
Asymmetrex Announces New Algorithms for Rapid Low Cost Counting of Therapeutic Tissue Stem Cells

In September 2016, stem cell biotechnology company Asymmetrex introduced its AlphaSTEM Test™ technology. The AlphaSTEM Test™ is the first, and still only, available technology that provides the cell-specific count or dose of tissue stem cells. Other technologies that attempt to provide information about the number and quality of therapeutic tissue stem cells are unable to distinguish them from more abundant non-stem progenitor cells. Although non-stem progenitor cells can have therapeutic effects, only tissue stem cells can provide long-term cures.

Although needed in academic stem cell research, stem cell biomanufacturing, and stem cell medicine, adoption of the AlphaSTEM Test™ has been limited. James Sherley, M.D., Ph.D., founder and director of Asymmetrex, attributes this initial response to two main factors. “There’s a lot of misinformation in the stem cell industry about the nature of tissue stem cell preparations and how counting stem cells specifically would solve many of the current problems faced by the industry and patients.” To address the need for better knowledge of the properties of tissue stem cells and their preparations, this week the company launched its recently developed podcast series on “Counting Stem Cells” on the international stem cell industry networking platform RegMedNet.

Today at the 6th Annual Congress of the Perinatal Stem Cell Society in Salt Lake City, Utah, Director Sherley will address what he thinks is the second cause of slow adoption of the company’s initial technology. “Our tech is an amazing advance for the stem cell industry, but it takes a lot of time to do – previously several weeks to get an answer – even though an answer available nowhere else; and it's rather expensive compared to other tests that confound the marketplace.” In his talk today, Sherley says, “Now, …everything will change.”

Using its computational strength, Asymmetrex has discovered mathematical algorithms that allow simple cell count data from a few days of culture to be used to calculate the stem cell-specific count of a sample. The new foundational stem cell algorithms address the need for timely, inexpensive stem cell-specific counting. The members of the Perinatal Stem Cell Society are an ideal audience for this first public report. Transplant therapies for children with leukemias have needed a means to insure sufficient blood stem cells for many years; and tissue stem cells from the umbilical cord are currently a major focus for the development of new stem cell therapies.

Asymmetrex is now accelerating its efforts to identify investors and industry partners who market basic cell counter devices. The company plans to integrate the new algorithms with existing electronic cell counters to develop the first tissue stem cell counters for tissue stem cell research, tissue stem cell biomanufacturing, and stem cell therapies.

About Asymmetrex

Asymmetrex, LLC is a Massachusetts life sciences company with a focus on developing technologies to advance stem cell medicine. Asymmetrex’s founder and director, James L. Sherley, M.D., Ph.D. is an internationally recognized expert on the unique properties of adult tissue stem cells. The company’s U.S. and U.K. patent portfolio contains biotechnologies that solve the two main technical problems – production and quantification – that have stood in the way of successful commercialization of human adult tissue stem cells for regenerative medicine and drug development. In addition, the portfolio includes novel technologies for isolating cancer stem cells and producing induced pluripotent stem cells for disease research purposes. Asymmetrex markets the first technology for determination of the dose and quality of tissue stem cell preparations (the “AlphaSTEM Test™”) for use in stem cell transplantation therapies and pre-clinical drug evaluations. Asymmetrex is a member company of the Advanced Regenerative Manufacturing Institute BioFabUSA and the Massachusetts Biotechnology Council.

Read the full story at

Source: PRWeb
Copyright©2020 Vocus, Inc.
All rights reserved

Related biology news :

1. Asymmetrex Partners in Manufacturing USA Institute
2. New Podcast Sponsored by Asymmetrex Increases Awareness to the Need for Stem Cell Dose in Stem Cell Treatments
3. Asymmetrex Approved to Conduct an ASTM Interlaboratory Evaluation of Its AlphaSTEM Test™ Technology as a Standard for Counting Therapeutic Adult Tissue Stem Cells
4. Asymmetrex Presents Proposal for ASTM Interlaboratory Evaluation of AlphaSTEM Test™ Technology Towards Establishing A Standard for Counting Therapeutic Stem Cells
5. Asymmetrex Publishes Chapter Explaining the Critical Need for Stem Cell Dosing for Success in Stem Cell Medicine
6. Asymmetrex Suggests a Stemgene Relief from Recent Cancer Woes About CRISPR-Cas9 Gene-Editing Therapies
7. Asymmetrex Proposes “Stemgene Therapy” to Emphasize the Importance of Tissue Stem Cells for Successful Gene Therapy
8. Vitamin Science Announces the Release of a Unique Eye Vitamin Formula for Blue Light Protection
9. Consulting firm dicentra announces new Ontario office located in Clarksburg
10. Tunnell Consulting Announces Appointment of Jonathan Horn as Principal
11. dicentra announces International Probiotic Association (IPA) membership
Post Your Comments:
(Date:7/10/2020)... ... July 09, 2020 , ... Today CJ BIO announced ... will share insight on the “fifth taste” phenomenon that is revolutionizing ingredient mixes, nutritional ... Advantage will be live on Monday, July 13, 2020 at11:00 AM (CDT) during SHIFT20, ...
(Date:7/1/2020)... , ... July 01, 2020 , ... ... it had completed the purchase of Teva-Takeda Pharmaceuticals’ packaging facility in Minakuchi, located ... existing Japanese clinical supply facility located in Kakegawa, the new 60,000-square-foot facility will ...
(Date:6/25/2020)... (PRWEB) , ... June 24, 2020 , ... ... cloud-based enterprise software and software-driven clinical data services that accelerate drug development, is ... low-dose selinexor, an XPO1 inhibitor, in hospitalized patients with severe COVID-19. This is ...
Breaking Biology News(10 mins):
(Date:9/1/2020)... ... 01, 2020 , ... Slone Partners , a nationwide ... placement of Julianne Averill , CPA, as Chief Financial Officer at ... implementing key business strategies to accelerate Alveo’s growth as the company advances its ...
(Date:8/15/2020)... ... 13, 2020 , ... Inc. magazine today revealed that Skysis ... of the nation’s fastest-growing private companies. The list represents a unique look at ... businesses. Intuit, Zappos, Under Armour, Microsoft, Patagonia, and many other well-known names gained ...
(Date:8/12/2020)... (PRWEB) , ... August 12, 2020 , ... ... Inc. (EMMA International), a global leader in FDA compliance consulting has been ... nation’s fastest-growing private companies. The list represents a unique look at the most ...
(Date:8/3/2020)... Ky. (PRWEB) , ... August 03, 2020 , ... Introducing ... products for transformative growth, , Known as MediVet Biologics since ... brand. , The new Ardent Animal Health will build on its base ...
Breaking Biology Technology: